Evidence explainerHuman · United States

What “Complete Remission” Means in a New Kidney-Treatment Approval

FDA’s obinutuzumab decision rests on a specific measure of proteinuria remission. That endpoint deserves explanation alongside the treatment’s risks.

Maya BellEditorial persona2 min read

A clinical-trial result becomes more useful when its label is explained.

FDA has approved obinutuzumab, marketed as Gazyva, for adults with primary membranous nephropathy at risk of disease progression, to induce remission of proteinuria. Its approvals index dates the announcement November 13, and the agency’s approval announcement is the source for what follows.

The agency describes MAJESTY, an open-label randomized study involving 142 adults and comparing obinutuzumab with tacrolimus. At week 104, complete remission occurred in 36% versus 6%. The endpoint required a urine protein-creatinine ratio no greater than 0.3 g/g, stable estimated kidney filtration, and no rescue therapy, treatment failure or early discontinuation. See FDA’s description of the study.

Those details prevent remission from becoming an undefined promise.

Evidence interpretation

A trial endpoint is a rule for assessing results. It tells readers what counted as success in that study. It should remain attached to the time point, comparison and population studied.

The two percentages also need the same label. Reporting only the treatment percentage would remove the comparison that helps explain the finding. Reporting the difference without explaining the endpoint would leave readers guessing what improved.

The study does not make every patient’s decision identical. The practical discussion concerns expected benefit, individual circumstances, monitoring and the risks a person would accept. FDA notes boxed warnings for hepatitis B reactivation and progressive multifocal leukoencephalopathy, a serious brain infection; see FDA’s safety information.

Uncertainty

This article reviews FDA’s approval summary, not the full trial report or prescribing information. It does not establish a cure, benefit for every kidney disease, or superiority over every alternative. It also does not assess availability or affordability.

A useful clinical conversation would clarify how the studied population relates to the individual, what monitoring is needed, and how treatment success would be assessed. This article cannot supply those individual answers.

Disclosure: This byline is a TiPH editorial persona, not a real individual. This article was prepared with AI assistance and reviewed and approved for publication by Elijah St. John. See our persona policy and AI assistance policy. Found an error? Contact TiPH. Material corrections will explain what changed and when. See our corrections policy.

Related on TiPH: Human health · Signal methodology · Global Signal Scan, November 15, 2026 · Latest news

Membranous nephropathyFDA approvalClinical trial endpointsKidney diseaseObinutuzumab
ShareShare on LinkedIn

How we reported this

How reported: Reviewed FDA’s public approval announcement and approvals index. No interviews, trial reanalysis or individual treatment advice. Maya Bell is an editorial persona, not a real person. This article was prepared with AI assistance on November 15, 2026, then reviewed and approved for publication by Elijah St. John, and first published November 17, 2026. It carries no interviews or fieldwork.

Source notes

Corrections & updates

Found an error? Contact TiPH. Material corrections will explain what changed and when.

Written by

Maya Bell

Editorial persona

The Explainer

The Explainer is the byline for explanatory journalism — taking a complicated system and making it make sense, without dumbing it down.

  • Explainers
  • Science communication
  • Systems

Maya Bell is a recurring editorial pen-name persona used by the Today in Public Health newsroom for explanatory journalism. It is not a real individual — no biography, credentials, employment history, or lived experience is implied or should be inferred. Every piece published under this byline is researched, written, and edited by real people who are accountable to our editorial standards.

Related stories